-
公开(公告)号：US09528086B2
公开(公告)日：2016-12-27
申请号：US14682155
申请日：2015-04-09
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Institut Pasteur de Lille , Universite Droit et Sante Lille II
发明人： Camille Locht , Nathalie Mielcarek , Hana Kammoun
CPC分类号： C12N1/36 , A61K39/092 , A61K39/099 , A61K39/12 , A61K2039/522 , A61K2039/523 , A61K2039/543 , C07K14/235 , C12N2760/16134 , C12N2760/18534
摘要： A genetically attenuated Bordetella pertussis strain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.
摘要翻译： 遗传减毒的百日咳杆菌菌株包括突变的百日咳毒素（ptx）基因和异源ampG基因，以及包含丝状血凝素（FHA）的N末端片段和异源表位或抗原蛋白或蛋白质片段的杂合蛋白 从FHA。 该菌株可用于减毒疫苗中用于治疗或预防感染性疾病。
-
2.发明申请公开(公告)号：US20150182614A1
公开(公告)日：2015-07-02
申请号：US14609461
申请日：2015-01-30
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Institut Pasteur de Lille , National University of Ireland Maynooth
发明人： Camille Locht , Bernard Mahon , Heather Kavanagh
IPC分类号： A61K39/02
CPC分类号： A61K39/099 , A61K2039/522 , A61K2039/523 , A61K2039/543 , A61K2039/544
摘要： The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
摘要翻译： 本发明涉及用于预防或治疗变应原驱动的气道病理学的气管细胞毒素（TCT），百日咳毒素（PTX）和皮肤坏死毒素（DNT））缺乏的生命衰弱的百日咳博德特氏菌疫苗。
-
公开(公告)号：US09730995B2
公开(公告)日：2017-08-15
申请号：US14860210
申请日：2015-09-21
CPC分类号： A61K39/099 , A61K2039/522 , A61K2039/523 , A61K2039/543
摘要： A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
-
公开(公告)号：US09180178B2
公开(公告)日：2015-11-10
申请号：US14658817
申请日：2015-03-16
CPC分类号： A61K39/099 , A61K2039/522 , A61K2039/523 , A61K2039/543
摘要： A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
摘要翻译： 提供了包含至少突变的ptx基因，缺失或突变的dnt基因和异源ampG基因的突变的博德氏菌属菌株。 减毒的突变型博德特氏菌属菌株可用于免疫原性组合物或用于治疗或预防博德氏杆菌感染的疫苗。 还提供了减毒的博德特氏菌属菌株用于制造疫苗或免疫原性组合物的用途，以及用于保护哺乳动物免受博德特氏菌感染的方法。
-
公开(公告)号：US20230364217A1
公开(公告)日：2023-11-16
申请号：US18303512
申请日：2023-04-19
申请人： Institut Pasteur de Lille , Institut National de la Sante et de la Recherche Medicale (INSERM) , National University of Singapore
IPC分类号： A61K39/02 , A61K39/12 , A61K39/145 , A61K9/00
CPC分类号： A61K39/099 , A61K39/12 , A61K39/145 , A61K9/0043 , A61K2039/522
摘要： The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
-
公开(公告)号：US20170106074A1
公开(公告)日：2017-04-20
申请号：US15353758
申请日：2016-11-17
申请人： Institut Pasteur de Lille , Institut National de la Sante et de la Recherche Medicale (INSERM) , National University of Singapore
CPC分类号： A61K39/099 , A61K9/0043 , A61K39/12 , A61K39/145 , A61K2039/521 , A61K2039/522 , A61K2039/523 , A61K2039/543 , A61K2039/55566 , A61K2039/58 , C12N2760/16134
摘要： The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
-
公开(公告)号：US10682377B2
公开(公告)日：2020-06-16
申请号：US15472436
申请日：2017-03-29
摘要： A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
-
公开(公告)号：US09839683B2
公开(公告)日：2017-12-12
申请号：US14609461
申请日：2015-01-30
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Institut Pasteur de Lille , National University of Ireland Maynooth
发明人： Camille Locht , Bernard Mahon , Heather Kavanagh
CPC分类号： A61K39/099 , A61K2039/522 , A61K2039/523 , A61K2039/543 , A61K2039/544
摘要： The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
-
公开(公告)号：US20170283890A1
公开(公告)日：2017-10-05
申请号：US15472436
申请日：2017-03-29
摘要： A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
-
10.发明申请公开(公告)号：US20180305416A1
公开(公告)日：2018-10-25
申请号：US15827151
申请日：2017-11-30
CPC分类号： C07K14/35 , A61K39/04 , A61K49/0006 , A61K2039/523 , A61K2039/53 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C07K2319/90
摘要： Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fission protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.032 秒)
